Cargando…

A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors

PURPOSE: Ridaforolimus is an investigational, potent, selective mTOR inhibitor. This study was conducted to determine the recommended phase 2 dose (RP2D), maximum tolerated dose, safety, pharmacokinetics, and antitumor activity of oral ridaforolimus in children with advanced solid tumors. EXPERIMENT...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pearson, Andrew D.J., Federico, Sara M., Aerts, Isabelle, Hargrave, Darren R., DuBois, Steven G., Iannone, Robert, Geschwindt, Ryan D., Wang, Ruixue, Haluska, Frank G., Trippett, Tanya M., Geoerger, Birgit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356695/ https://www.ncbi.nlm.nih.gov/pubmed/27713169 http://dx.doi.org/10.18632/oncotarget.12450

Ejemplares similares

Ridaforolimus
Publicado: (2012)

Vorinostat synergizes with ridaforolimus and abrogates the ridaforolimus-induced activation of AKT in synovial sarcoma cells
por: Morgan, Sherif S, et al.
Publicado: (2014)

Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer
por: Becker, Marc A., et al.
Publicado: (2016)

Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial
por: Colombo, N, et al.
Publicado: (2013)

A phase I study of ridaforolimus in adult Chinese patients with advanced solid tumors
por: Liu, Lian, et al.
Publicado: (2013)

Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600–Mutant Low-Grade Glioma
por: Bouffet, Eric, et al.
Publicado: (2023)

Cobimetinib in Pediatric and Young Adult Patients with Relapsed or Refractory Solid Tumors (iMATRIX-cobi): A Multicenter, Phase I/II Study
por: Trippett, Tanya, et al.
Publicado: (2022)

Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers
por: Chon, Hye Sook, et al.
Publicado: (2017)

Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors
por: Seki, Yoshitaka, et al.
Publicado: (2011)

Treating metastatic soft-tissue or bone sarcomas – potential role of ridaforolimus
por: Keedy, Vicki L
Publicado: (2012)

Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models
por: SQUILLACE, RACHEL M., et al.
Publicado: (2012)

Dabrafenib, alone or in combination with trametinib, in BRAF V600–mutated pediatric Langerhans cell histiocytosis
por: Whitlock, James A., et al.
Publicado: (2023)

Pharmacokinetic Evaluation of a DSPE-PEG(2000) Micellar Formulation of Ridaforolimus in Rat
por: Remsberg, Connie M., et al.
Publicado: (2012)

A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours
por: Brana, I, et al.
Publicado: (2014)

LGG-49. SAFETY AND EFFICACY OF TRAMETINIB (T) MONOTHERAPY AND DABRAFENIB + TRAMETINIB (D+T) COMBINATION THERAPY IN PEDIATRIC PATIENTS WITH BRAF V600-MUTANT LOW-GRADE GLIOMA (LGG)
por: Bouffet, Eric, et al.
Publicado: (2020)

Population pharmacokinetics–pharmacodynamics of sunitinib in pediatric patients with solid tumors
por: Wang, Erjian, et al.
Publicado: (2020)

A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer
por: Lush, Richard M., et al.
Publicado: (2012)

Multimodal immunogenomic biomarker analysis of tumors from pediatric patients enrolled to a phase 1-2 study of single-agent atezolizumab
por: Nabbi, Arash, et al.
Publicado: (2023)

Precision medicine in pediatric oncology
por: Forrest, Suzanne J., et al.
Publicado: (2018)

Population Pharmacokinetics of Sunitinib and its Active Metabolite SU012662 in Pediatric Patients with Gastrointestinal Stromal Tumors or Other Solid Tumors
por: Wang, Erjian, et al.
Publicado: (2021)

Relevance of Fusion Genes in Pediatric Cancers: Toward Precision Medicine
por: Dupain, Célia, et al.
Publicado: (2017)

A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors
por: Becher, Oren J., et al.
Publicado: (2017)

EPCT-08. ACTIVITY OF LAROTRECTINIB IN PEDIATRIC TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION CANCER PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS
por: Goto, Hiroaki, et al.
Publicado: (2020)

Potent in vitro and xenograft antitumor activity of a novel agent, PV-10, against relapsed and refractory neuroblastoma
por: Swift, Lucy, et al.
Publicado: (2019)

Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study
por: Casanova, Michela, et al.
Publicado: (2023)

Tuberculosis in Pediatric Solid Organ and Hematopoietic Stem Cell Recipients
por: Dubois, Melanie, et al.
Publicado: (2021)

Clinical Characteristics and Outcomes of Pediatric Patients with Desmoplastic Small Round Cell Tumor
por: Bent, Melissa A., et al.
Publicado: (2016)

The National Institute of Allergy and Infectious Diseases Decision to Stop the Adaptive COVID-19 Trial: On Solid Ethical and Scientific Grounds
por: Mozersky, Jessica, et al.
Publicado: (2020)

Noninvasive rodent cardiac output: comparison of a compact clinical monitor with echocardiography and proposal of a simple correction factor
por: Sturgess, DJ, et al.
Publicado: (2008)

Los primeros jinetes /
por: Trippett, Frank
Publicado: (1977)

Emergency room imaging in pediatric patients with cancer: analysis of the spectrum and frequency of imaging modalities and findings in a tertiary cancer center and their relationship with survival
por: Woo, Sungmin, et al.
Publicado: (2021)

SFCE-RAPIRI Phase I Study of Rapamycin Plus Irinotecan: A New Way to Target Intra-Tumor Hypoxia in Pediatric Refractory Cancers
por: Jannier, Sarah, et al.
Publicado: (2020)

Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors
por: Mascarenhas, Leo, et al.
Publicado: (2021)

Sepsis-associated diastolic dysfunction without elevated plasma B-type natriuretic peptide
por: Sturgess, DJ, et al.
Publicado: (2008)

Effects of food on the pharmacokinetics of ponatinib in healthy subjects
por: Narasimhan, NI, et al.
Publicado: (2013)

RARE-07. EFFICACY AND SAFETY OF LAROTRECTINIB IN PEDIATRIC PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION-POSITIVE PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS
por: Perreault, Sébastien, et al.
Publicado: (2021)

Parental Attitudes toward Artificial Intelligence-Driven Precision Medicine Technologies in Pediatric Healthcare
por: Sisk, Bryan A., et al.
Publicado: (2020)

Margins Matter: current radiation therapy practice and future directions
por: Hargrave, Catriona, et al.
Publicado: (2017)

Communication interventions in adult and pediatric oncology: A scoping review and analysis of behavioral targets
por: Sisk, Bryan A., et al.
Publicado: (2019)

Aids for the Optical Analysis of Electrophoretic Diagrams
por: Stern, Kurt G., et al.
Publicado: (1941)

Cannot write session to /tmp/vufind_sessions/sess_alonb21k3oo57s0cdtami84v6m